In this episode of the Diabetes Innovators Series, Rob interviews Dr. Anath

Shalev discussing the recent advancements in TIXiMed's TIX100, an oral

therapy for type 1 diabetes. The conversation covers the successful

completion of a phase one study, the implications of the results, and the

potential impact of TIX100 on diabetes management. Dr. Shalev emphasizes

the importance of addressing beta cell dysfunction and the exciting

metabolic signals observed during the study. The discussion also touches on

the future directions for TIX100 and its role in improving the lives of

diabetes patients.

Chapters

Chapters

00:00 Introduction to TixiMed and TIX100

01:16 Phase One Study Results and Implications

05:22 Metabolic Signals and Future Studies

08:11 The Role of TIX100 in Diabetes Management

09:47 Future Directions and Patient Impact

Resources:

TIXiMED

Dr. Anath Shalev